SE0100903D0 - Compounds - Google Patents

Compounds

Info

Publication number
SE0100903D0
SE0100903D0 SE0100903A SE0100903A SE0100903D0 SE 0100903 D0 SE0100903 D0 SE 0100903D0 SE 0100903 A SE0100903 A SE 0100903A SE 0100903 A SE0100903 A SE 0100903A SE 0100903 D0 SE0100903 D0 SE 0100903D0
Authority
SE
Sweden
Prior art keywords
compounds
inhibitors
mmp12
useful
formula
Prior art date
Application number
SE0100903A
Other languages
English (en)
Swedish (sv)
Inventor
Matti Lepistoe
Af Rosenschoeld Magnus Munck
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0100903A priority Critical patent/SE0100903D0/xx
Publication of SE0100903D0 publication Critical patent/SE0100903D0/xx
Priority to KR1020037011980A priority patent/KR100865836B1/ko
Priority to BR0207985-2A priority patent/BR0207985A/pt
Priority to EEP200300450A priority patent/EE200300450A/xx
Priority to IL15757002A priority patent/IL157570A0/xx
Priority to CNA028100417A priority patent/CN1509275A/zh
Priority to CNA028099273A priority patent/CN1509274A/zh
Priority to PL02364714A priority patent/PL364714A1/xx
Priority to PL02365107A priority patent/PL365107A1/xx
Priority to IL15765802A priority patent/IL157658A0/xx
Priority to IL15765002A priority patent/IL157650A0/xx
Priority to CZ20032502A priority patent/CZ20032502A3/cs
Priority to EP02704038A priority patent/EP1370538A1/en
Priority to US10/471,501 priority patent/US20040116486A1/en
Priority to HU0400206A priority patent/HUP0400206A3/hu
Priority to US10/471,808 priority patent/US20040147573A1/en
Priority to CA002440475A priority patent/CA2440475A1/en
Priority to CNB028097890A priority patent/CN1313448C/zh
Priority to JP2002573758A priority patent/JP2004523582A/ja
Priority to CZ20032498A priority patent/CZ20032498A3/cs
Priority to CA002444526A priority patent/CA2444526A1/en
Priority to RU2003127731/04A priority patent/RU2003127731A/ru
Priority to JP2002573759A priority patent/JP2004527511A/ja
Priority to PCT/SE2002/000475 priority patent/WO2002074750A1/en
Priority to US10/471,499 priority patent/US20040110809A1/en
Priority to BR0208062-1A priority patent/BR0208062A/pt
Priority to MXPA03008183A priority patent/MXPA03008183A/es
Priority to RU2003127732/04A priority patent/RU2003127732A/ru
Priority to UA2003098167A priority patent/UA77169C2/uk
Priority to HU0400193A priority patent/HUP0400193A3/hu
Priority to MXPA03008180A priority patent/MXPA03008180A/es
Priority to JP2002573761A priority patent/JP2004527512A/ja
Priority to HU0400328A priority patent/HUP0400328A3/hu
Priority to MXPA03008187A priority patent/MXPA03008187A/es
Priority to UA2003098169A priority patent/UA74624C2/uk
Priority to SK1093-2003A priority patent/SK10932003A3/sk
Priority to PCT/SE2002/000474 priority patent/WO2002074749A1/en
Priority to PCT/SE2002/000479 priority patent/WO2002074752A1/en
Priority to MYPI20020912A priority patent/MY129188A/en
Priority to CA002440632A priority patent/CA2440632A1/en
Priority to NZ528141A priority patent/NZ528141A/en
Priority to EEP200300452A priority patent/EE200300452A/xx
Priority to EEP200300439A priority patent/EE200300439A/xx
Priority to PL02364705A priority patent/PL364705A1/xx
Priority to KR10-2003-7011989A priority patent/KR20030082990A/ko
Priority to CZ20032501A priority patent/CZ20032501A3/cs
Priority to EP02704034A priority patent/EP1370536A1/en
Priority to AU2002237633A priority patent/AU2002237633B2/en
Priority to RU2003127736/04A priority patent/RU2293730C2/ru
Priority to BR0208105-9A priority patent/BR0208105A/pt
Priority to EP02704033A priority patent/EP1370535A1/en
Priority to SK1091-2003A priority patent/SK10912003A3/sk
Priority to SK1094-2003A priority patent/SK10942003A3/sk
Priority to NZ528108A priority patent/NZ528108A/en
Priority to KR10-2003-7011983A priority patent/KR20030082988A/ko
Priority to ARP020100945A priority patent/AR035444A1/es
Priority to ZA200306738A priority patent/ZA200306738B/en
Priority to ZA200306733A priority patent/ZA200306733B/en
Priority to IS6945A priority patent/IS6945A/is
Priority to IS6944A priority patent/IS6944A/is
Priority to NO20034025A priority patent/NO20034025L/no
Priority to NO20034032A priority patent/NO20034032L/no
Priority to IS6948A priority patent/IS6948A/is
Priority to NO20034027A priority patent/NO326088B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
SE0100903A 2001-03-15 2001-03-15 Compounds SE0100903D0 (sv)

Priority Applications (64)

Application Number Priority Date Filing Date Title
SE0100903A SE0100903D0 (sv) 2001-03-15 2001-03-15 Compounds
KR1020037011980A KR100865836B1 (ko) 2001-03-15 2002-03-13 메탈로프로테이나제 억제제
BR0207985-2A BR0207985A (pt) 2001-03-15 2002-03-13 Inibidores de metaloproteinase
EEP200300450A EE200300450A (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid
IL15757002A IL157570A0 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CNA028100417A CN1509275A (zh) 2001-03-15 2002-03-13 金属蛋白酶抑制剂
CNA028099273A CN1509274A (zh) 2001-03-15 2002-03-13 金属蛋白酶抑制剂
PL02364714A PL364714A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
PL02365107A PL365107A1 (en) 2001-03-15 2002-03-13 Compounds
IL15765802A IL157658A0 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
IL15765002A IL157650A0 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CZ20032502A CZ20032502A3 (cs) 2001-03-15 2002-03-13 Inhibitory metalloproteinasy
EP02704038A EP1370538A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
US10/471,501 US20040116486A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
HU0400206A HUP0400206A3 (en) 2001-03-15 2002-03-13 Imidazolidindion derivatives having metalloproteinase inhibitor effect a their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing them
US10/471,808 US20040147573A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CA002440475A CA2440475A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CNB028097890A CN1313448C (zh) 2001-03-15 2002-03-13 金属蛋白酶抑制剂
JP2002573758A JP2004523582A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
CZ20032498A CZ20032498A3 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CA002444526A CA2444526A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
RU2003127731/04A RU2003127731A (ru) 2001-03-15 2002-03-13 Ингибиторы металлопротеиназ
JP2002573759A JP2004527511A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
PCT/SE2002/000475 WO2002074750A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
US10/471,499 US20040110809A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
BR0208062-1A BR0208062A (pt) 2001-03-15 2002-03-13 Inibidores de metaloproteinase
MXPA03008183A MXPA03008183A (es) 2001-03-15 2002-03-13 Inhibidores de metaloproteinasa.
RU2003127732/04A RU2003127732A (ru) 2001-03-15 2002-03-13 Ингибиторы металлопротеиназ
UA2003098167A UA77169C2 (en) 2001-03-15 2002-03-13 Hidantoine derivatives, pharmaceutical composition, their use
HU0400193A HUP0400193A3 (en) 2001-03-15 2002-03-13 Imidazolindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
MXPA03008180A MXPA03008180A (es) 2001-03-15 2002-03-13 Inhibidores de metaloproteinasa.
JP2002573761A JP2004527512A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
HU0400328A HUP0400328A3 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitor azoles and pharmaceutical compositions containing them
MXPA03008187A MXPA03008187A (es) 2001-03-15 2002-03-13 Inhibidores de metaloproteinasas.
UA2003098169A UA74624C2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
SK1093-2003A SK10932003A3 (sk) 2001-03-15 2002-03-13 Metaloproteinázové inhibítory
PCT/SE2002/000474 WO2002074749A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
PCT/SE2002/000479 WO2002074752A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
MYPI20020912A MY129188A (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CA002440632A CA2440632A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
NZ528141A NZ528141A (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
EEP200300452A EE200300452A (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid
EEP200300439A EE200300439A (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid
PL02364705A PL364705A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
KR10-2003-7011989A KR20030082990A (ko) 2001-03-15 2002-03-13 메탈로프로테이나제 억제제
CZ20032501A CZ20032501A3 (cs) 2001-03-15 2002-03-13 Inhibitory metaloproteinasy
EP02704034A EP1370536A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
AU2002237633A AU2002237633B2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
RU2003127736/04A RU2293730C2 (ru) 2001-03-15 2002-03-13 Ингибиторы металлопротеиназ, их применение и фармацевтические композиции на их основе
BR0208105-9A BR0208105A (pt) 2001-03-15 2002-03-13 Inibidores de metaloproteinase
EP02704033A EP1370535A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
SK1091-2003A SK10912003A3 (sk) 2001-03-15 2002-03-13 Metaloproteinázové inhibítory
SK1094-2003A SK10942003A3 (sk) 2001-03-15 2002-03-13 Metaloproteinázové inhibítory
NZ528108A NZ528108A (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
KR10-2003-7011983A KR20030082988A (ko) 2001-03-15 2002-03-13 메탈로프로테이나제 억제제
ARP020100945A AR035444A1 (es) 2001-03-15 2002-03-15 Compuestos inhibidores de metaloproteinasas, composicion farmaceutica, metodo de tratamiento, y uso de estos compuestos para la preparacion de medicamentos
ZA200306738A ZA200306738B (en) 2001-03-15 2003-08-28 Metalloproteinase inhibitors.
ZA200306733A ZA200306733B (en) 2001-03-15 2003-08-28 Metalloproteinase inhibitors.
IS6945A IS6945A (is) 2001-03-15 2003-09-10 Málmpróteinasatálmar
IS6944A IS6944A (is) 2001-03-15 2003-09-10 Málmpróteinasatálmar
NO20034025A NO20034025L (no) 2001-03-15 2003-09-11 Metalloproteinaseinhibitorer
NO20034032A NO20034032L (no) 2001-03-15 2003-09-11 Metallproteinase-inhibitorer
IS6948A IS6948A (is) 2001-03-15 2003-09-11 M βlmproteinasat βlmar
NO20034027A NO326088B1 (no) 2001-03-15 2003-09-11 Metalloproteinaseinhibitorer, farmasoytiske sammensetninger inneholdende slike samt anvendelser derav

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100903A SE0100903D0 (sv) 2001-03-15 2001-03-15 Compounds

Publications (1)

Publication Number Publication Date
SE0100903D0 true SE0100903D0 (sv) 2001-03-15

Family

ID=20283375

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0100903A SE0100903D0 (sv) 2001-03-15 2001-03-15 Compounds

Country Status (25)

Country Link
US (2) US20040110809A1 (sk)
EP (2) EP1370535A1 (sk)
JP (2) JP2004527512A (sk)
KR (2) KR20030082988A (sk)
CN (2) CN1509274A (sk)
AR (1) AR035444A1 (sk)
AU (1) AU2002237633B2 (sk)
BR (2) BR0208062A (sk)
CA (2) CA2440475A1 (sk)
CZ (2) CZ20032498A3 (sk)
EE (2) EE200300450A (sk)
HU (2) HUP0400193A3 (sk)
IL (2) IL157650A0 (sk)
IS (2) IS6945A (sk)
MX (2) MXPA03008183A (sk)
MY (1) MY129188A (sk)
NO (2) NO20034032L (sk)
NZ (2) NZ528108A (sk)
PL (2) PL364705A1 (sk)
RU (2) RU2293730C2 (sk)
SE (1) SE0100903D0 (sk)
SK (2) SK10912003A3 (sk)
UA (2) UA74624C2 (sk)
WO (2) WO2002074752A1 (sk)
ZA (2) ZA200306738B (sk)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
US7005439B2 (en) * 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
ES2333412T3 (es) 2001-05-25 2010-02-22 Bristol-Myers Squibb Company Derivados de hidantoina como inhibidores de metaloproteinasas de matriz.
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202692D0 (sv) * 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
FR2845000B1 (fr) * 2002-09-27 2005-05-27 Oreal Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
JP5042833B2 (ja) * 2004-08-19 2012-10-03 クエスト ファーマシューティカル サーヴィシーズ マクロファージエラスターゼの阻害剤としての５−［３−（４−ベンジルオキシフェニルチオ）−フラ−２−イル］−イミダゾリジン−２，４−ジオン及び類似体
JPWO2006051937A1 (ja) * 2004-11-15 2008-05-29 塩野義製薬株式会社 ヘテロ５員環誘導体
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200740769A (en) * 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
KR20090018104A (ko) 2006-05-08 2009-02-19 어리어드 파마슈티칼스, 인코포레이티드 아세틸렌계 헤테로아릴 화합물
EA200870515A1 (ru) 2006-05-08 2009-06-30 Ариад Фармасьютикалз, Инк. Моноциклические гетероарильные соединения
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
ES2313841B1 (es) * 2007-06-26 2010-01-12 Proyecto De Biomedicina Cima, S.L. Composiciones para tratamiento anti-fibrinolitico.
CA2743449C (en) 2008-11-12 2016-10-18 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
HUE060533T2 (hu) 2016-12-16 2023-03-28 Pfizer GLP-1 receptor agonisták és alkalmazásuk
FI3793992T3 (fi) 2018-05-15 2024-04-17 Foresee Pharmaceuticals Usa Inc Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2745875A (en) * 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) * 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) * 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
US3849574A (en) * 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS61212292A (ja) * 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
JPH0597814A (ja) * 1991-10-02 1993-04-20 Ajinomoto Co Inc ５−（ヒドロキシメチル）ヒダントイン誘導体の製法
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
EP0640594A1 (en) * 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
NZ322565A (en) * 1995-11-22 1999-11-29 Darwin Discovery Ltd Mercaptoalkykpeptidyl compounds having an imidazole substitutent and their use as inhibitors of matrix metalloproteinases and tumor necrosis factor
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
AU4812697A (en) * 1996-10-22 1998-05-15 Pharmacia & Upjohn Company Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors
EP0983239A1 (en) * 1997-05-06 2000-03-08 Novo Nordisk A/S Novel heterocyclic compounds
DK0877019T3 (da) * 1997-05-09 2002-04-08 Hoechst Ag Substituerede diaminocarboxylsyrer
NZ501166A (en) * 1997-07-31 2001-12-21 Abbott Lab Reverse hydroxamate-containing compounds and their use as inhibitors of matrix metalloproteinases
CN1195735C (zh) * 1998-02-04 2005-04-06 诺瓦提斯公司 抑制使基质退化的金属蛋白酶的磺酰氨基衍生物
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
CA2330095A1 (en) * 1998-05-14 1999-11-18 Dupont Pharmaceuticals Company Substituted aryl hydroxamic acids as metalloproteinase inhibitors
WO1999065867A1 (en) * 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
DE69915004T2 (de) * 1998-11-05 2004-09-09 Pfizer Products Inc., Groton 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
AU1817700A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6340691B1 (en) * 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US20020006920A1 (en) * 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
EP1078923B1 (en) * 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
DE60023012T2 (de) * 1999-08-12 2006-07-20 Pharmacia Italia S.P.A. 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US20020065219A1 (en) * 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
US20020091107A1 (en) * 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
WO2002074750A1 (en) * 2001-03-15 2002-09-26 Astrazeneca Ab Metalloproteinase inhibitors
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
ES2333412T3 (es) * 2001-05-25 2010-02-22 Bristol-Myers Squibb Company Derivados de hidantoina como inhibidores de metaloproteinasas de matriz.
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
TWI220073B (en) * 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
WO2002074752A1 (en) 2002-09-26
CN1313448C (zh) 2007-05-02
NZ528108A (en) 2005-04-29
CZ20032501A3 (cs) 2004-02-18
UA77169C2 (en) 2006-11-15
EP1370535A1 (en) 2003-12-17
AU2002237633B2 (en) 2007-04-05
NO20034027L (no) 2003-11-05
SK10912003A3 (sk) 2004-05-04
ZA200306733B (en) 2004-11-29
HUP0400193A2 (hu) 2004-07-28
MXPA03008187A (es) 2004-01-29
KR20030082988A (ko) 2003-10-23
NO20034032L (no) 2003-11-10
NO326088B1 (no) 2008-09-15
CA2440475A1 (en) 2002-09-26
US20040116486A1 (en) 2004-06-17
CN1509274A (zh) 2004-06-30
PL365107A1 (en) 2004-12-27
RU2003127736A (ru) 2005-03-27
PL364705A1 (en) 2004-12-13
HUP0400328A2 (hu) 2004-09-28
BR0208062A (pt) 2004-03-02
MY129188A (en) 2007-03-30
WO2002074749A1 (en) 2002-09-26
NZ528141A (en) 2005-05-27
US20040110809A1 (en) 2004-06-10
AR035444A1 (es) 2004-05-26
KR20030082985A (ko) 2003-10-23
EE200300450A (et) 2003-12-15
CA2444526A1 (en) 2002-09-26
KR100865836B1 (ko) 2008-10-29
EE200300452A (et) 2004-02-16
IL157658A0 (en) 2004-03-28
HUP0400193A3 (en) 2004-10-28
JP2004527512A (ja) 2004-09-09
RU2003127731A (ru) 2005-03-20
ZA200306738B (en) 2004-11-29
IS6948A (is) 2003-09-11
CZ20032498A3 (en) 2004-03-17
BR0207985A (pt) 2004-06-15
MXPA03008183A (es) 2003-12-12
HUP0400328A3 (en) 2007-05-29
WO2002074752A8 (en) 2004-04-22
SK10942003A3 (sk) 2004-04-06
NO20034032D0 (no) 2003-09-11
IS6945A (is) 2003-09-10
JP2004523582A (ja) 2004-08-05
IL157650A0 (en) 2004-03-28
UA74624C2 (en) 2006-01-16
NO20034027D0 (no) 2003-09-11
RU2293730C2 (ru) 2007-02-20
CN1509273A (zh) 2004-06-30
EP1370538A1 (en) 2003-12-17

Similar Documents

Publication Publication Date Title
SE0100903D0 (sv) Compounds
SE0100902D0 (sv) Compounds
DE69809187T2 (de) Metalloproteinase-Inhibitoren
NO20041493L (no) Kjemiske forbindelser.
DK1385515T3 (da) Spiropyrazole forbindelser
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
WO2004083174A3 (en) Sulfonyl-amidino containing and tetrahydropyrimidino containing compounds as factor xa inhibitors
DE60335359D1 (de) Phthalazinonderivate
SE0000540D0 (sv) New compounds
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
SE0103710D0 (sv) Compounds
UY28014A1 (es) Compuestos quimicos
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
DE69812634D1 (de) Metalloproteinase-inhibitoren
NO20021409L (no) Hastighets-kontrollerte partikler
PT1419163E (pt) Imidazopiridinas triciclicas
MY128164A (en) Compounds
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
NO20015892L (no) Inhibitorer av metallproteinaser
BRPI0416678A (pt) pirazolpirimidinas
DK1562604T3 (da) Prostaglandinforbindelser til behandling af fedme
ATE349427T1 (de) Tryptaseinhibitoren
SE0403003D0 (sv) Chemical compound 1
GB0314299D0 (en) Chemical compounds
WO2002083696A3 (en) Novel cyclo azaphospha hydrocarbons